DK0687184T3 - Rekombinante adenoviruser og anvendelse deraf ved genterapi til behandling af øjensygdomme - Google Patents

Rekombinante adenoviruser og anvendelse deraf ved genterapi til behandling af øjensygdomme

Info

Publication number
DK0687184T3
DK0687184T3 DK94908383T DK94908383T DK0687184T3 DK 0687184 T3 DK0687184 T3 DK 0687184T3 DK 94908383 T DK94908383 T DK 94908383T DK 94908383 T DK94908383 T DK 94908383T DK 0687184 T3 DK0687184 T3 DK 0687184T3
Authority
DK
Denmark
Prior art keywords
eye diseases
treatment
recombinant adenoviruses
gene therapy
adenoviruses
Prior art date
Application number
DK94908383T
Other languages
English (en)
Inventor
Pascale Briand
Michel Perricaudet
Original Assignee
Inst Nat Sante Rech Med
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Aventis Pharma Sa filed Critical Inst Nat Sante Rech Med
Application granted granted Critical
Publication of DK0687184T3 publication Critical patent/DK0687184T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DK94908383T 1993-03-03 1994-02-28 Rekombinante adenoviruser og anvendelse deraf ved genterapi til behandling af øjensygdomme DK0687184T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9302438A FR2702152B1 (fr) 1993-03-03 1993-03-03 Virus recombinants et leur utilisation en thérapie génique.
PCT/FR1994/000220 WO1994020146A1 (fr) 1993-03-03 1994-02-28 Adenovirus recombinants et leur utilisation en therapie genique pour le traitement des pathologies oculaires

Publications (1)

Publication Number Publication Date
DK0687184T3 true DK0687184T3 (da) 2002-10-28

Family

ID=9444602

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94908383T DK0687184T3 (da) 1993-03-03 1994-02-28 Rekombinante adenoviruser og anvendelse deraf ved genterapi til behandling af øjensygdomme

Country Status (15)

Country Link
EP (1) EP0687184B1 (da)
JP (1) JP3835809B2 (da)
AT (1) ATE220923T1 (da)
AU (1) AU693782B2 (da)
CA (1) CA2154355A1 (da)
DE (1) DE69431046T2 (da)
DK (1) DK0687184T3 (da)
ES (1) ES2181710T3 (da)
FR (1) FR2702152B1 (da)
HU (1) HU218900B (da)
NO (1) NO319571B1 (da)
NZ (1) NZ262135A (da)
PT (1) PT687184E (da)
WO (1) WO1994020146A1 (da)
ZA (1) ZA941426B (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5792751A (en) * 1992-04-13 1998-08-11 Baylor College Of Medicine Tranformation of cells associated with fluid spaces
FR2717823B1 (fr) * 1994-03-23 1996-04-26 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
IL113052A0 (en) * 1994-03-23 1995-06-29 Rhone Poulenc Rorer Sa Recombinant viruses, their preparation and their use in gene therapy
FR2726575B1 (fr) * 1994-11-09 1996-12-20 Rhone Poulenc Rorer Sa Virus recombinants, preparation et utilisation en therapie genique
FR2717824B1 (fr) * 1994-03-25 1996-04-26 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
FR2718150B1 (fr) * 1994-03-29 1996-04-26 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
US5827702A (en) 1994-10-31 1998-10-27 Genentech, Inc. Ocular gene therapy
US6107027A (en) * 1994-12-14 2000-08-22 University Of Washington Ribozymes for treating hepatitis C
US6696423B1 (en) 1997-08-29 2004-02-24 Biogen, Inc. Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
US6489305B1 (en) 1998-05-08 2002-12-03 Canji, Inc. Methods and compositions for the treatment of ocular diseases
EP1246642B1 (fr) * 1999-12-30 2005-09-07 Aventis Pharma S.A. Utilisation d'un vecteur comprenant un acide nucleique codant pour un facteur anti-angiogenique pour le traitement des neovascularisations corneennes
FR2803207B1 (fr) * 1999-12-30 2004-04-30 Aventis Pharma Sa Utilisation d'un vecteur comprenant un acide nucleique codant pour un facteur anti-angiogenique pour le traitement des neovascularisations corneennes
US6821775B1 (en) 2000-02-11 2004-11-23 Genvec, Inc. Viral vector encoding pigment epithelium-derived factor
US20030158112A1 (en) 2002-02-15 2003-08-21 Johns Hopkins University School Of Medicine Selective induction of apoptosis to treat ocular disease
EP1692154A4 (en) 2003-11-24 2009-07-08 Canji Inc REDUCTION OF SKIN TEMPERING
DK2229956T3 (da) 2004-09-13 2013-07-29 Genzyme Corp Multimere konstruktioner
PL2601214T3 (pl) 2010-08-06 2018-05-30 Genzyme Corporation Kompozycje antagonistyczne wobec VEGF oraz ich zastosowania

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1336678C (en) * 1988-09-13 1995-08-15 David L. Berliner Prophylaxis and treatment of nervous system diseases with melanin
WO1992017211A1 (en) * 1991-04-05 1992-10-15 Edison Animal Biotechnology Center, Ohio University Retrovirus inhibition with antisense nucleic acids complementary to packaging sequences

Also Published As

Publication number Publication date
NO953329L (no) 1995-08-24
ZA941426B (en) 1994-10-04
JP3835809B2 (ja) 2006-10-18
WO1994020146A1 (fr) 1994-09-15
HU218900B (hu) 2000-12-28
NO953329D0 (no) 1995-08-24
DE69431046T2 (de) 2003-02-13
ATE220923T1 (de) 2002-08-15
EP0687184B1 (fr) 2002-07-24
NO319571B1 (no) 2005-08-29
NZ262135A (en) 2000-12-22
PT687184E (pt) 2002-12-31
EP0687184A1 (fr) 1995-12-20
CA2154355A1 (fr) 1994-09-15
FR2702152A1 (fr) 1994-09-09
ES2181710T3 (es) 2003-03-01
DE69431046D1 (de) 2002-08-29
AU6144494A (en) 1994-09-26
FR2702152B1 (fr) 1995-05-24
AU693782B2 (en) 1998-07-09
HUT73215A (en) 1996-06-28
HU9502573D0 (en) 1995-10-30
JPH08509208A (ja) 1996-10-01

Similar Documents

Publication Publication Date Title
DK0687184T3 (da) Rekombinante adenoviruser og anvendelse deraf ved genterapi til behandling af øjensygdomme
ATE255128T1 (de) Peptid-immitierende substanzen in der krebstherapie
DK0698108T3 (da) Adenovirale vektorer af animalsk oprindelse og deres anvendelse ved genterapi
DK19488A (da) Bestraalingsandordning til brug ved medicinsk behandling af naese- og halspassager
DK0751709T3 (da) Anvendelse af Bcl-2 til fremstilling af lægemidler til terapeutisk behandling og forebyggelse af sygdomme
DK0668763T3 (da) Anvendelse af phenserin til fremstillingen af lægemidler til behandlingen af kognitive sygdomme
DK85786A (da) Biologisk aktive fragmenter af human antihaemofilisk faktor og fremgangsmaade til fremstilling deraf
ATE380548T1 (de) Verwendung von p53 inhibitoren zur behandlung von nebenerscheinungen bei der krebstherapie
NO972451L (no) Heterosyklyloksy- og tiometyl-1,2,5-tiadiazolidin-3-on 1,1-dioksyder og preparater og fremgangsmåte for anvendelse derav
DK0517820T3 (da) Anvendelse af 3-guanidinopropionsyre ved fremstillingen af et lægemiddel til behandling og hindring af overdreven fedme
DK0914144T3 (da) Terapeutiske anvendelser af BPI-protein-produkter til human meningokokæmi
JPS57193411A (en) Prevention of prostatic hyperplasia and therapeutical drug
ATE247709T1 (de) 3'utr des menschliches prohibitin-gens
SG50419A1 (en) Methods of therapeutic and anaesthetic treatment and preparations therefor
NO984196L (no) FremgangsmÕte for behandling av stoffmisbruk
DK131189D0 (da) Fremgangsmaade og middel til ophthalmisk anaestesi
AU3053595A (en) Therapeutic treatment and preparations
UA22007A (uk) Спосіб лікуваhhя хроhічhого hеспецифічhого простатиту
UA29648A (uk) Спосіб лікування хімічних опіків стравоходу
MX9706569A (es) Virus recombinantes que expresan la lecitina-colesterol aciltransferasa y sus usos en terapia genica.
UA12890A (uk) Спосіб акупуhктури
ZA93199B (en) An apparatus for use in therapeutic and/or medical treatment.
DK68191D0 (da) Fremgangsmaade og apparat til lokalisering og behandling af skader og funktionsforstyrrelser i en patients hjerne
GEP19981480B (en) Method for Treating Vertebral Column
DE69822234D1 (de) Verwendung von Olanzapin zur Herstellung eines Arzneimittels zur Neuroprotektion